Guidelines for drug prescription in patients with the acute porphyrias.
Certain drugs are well known to cause acute neurological crises in patients with hereditary coproporphyria, variegate porphyria and acute intermittent porphyria. Guidelines for drug therapy have been provided in this article, particular attention being paid to the manner in which the porphyrogenicity or safety of a drug has been assessed and providing full references to the original reports to allow further research if necessary.
D000208:Acute Disease; D000700:Analgesics / Q000009:adverse effects; D000777:Anesthetics; D014151:Anti-Anxiety Agents / Q000009:adverse effects; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000893:Anti-Inflammatory Agents / Q000009:adverse effects; D000927:Anticonvulsants / Q000009:adverse effects; D000959:Antihypertensive Agents / Q000009:adverse effects; D000962:Antimalarials / Q000627:therapeutic use; D000697:Central Nervous System Stimulants / Q000009:adverse effects; D004232:Diuretics / Q000009:adverse effects; D004341:Drug Evaluation; D064420:Drug-Related Side Effects and Adverse Reactions; D000431:Ethanol / Q000009:adverse effects; D006801:Humans; D011164:Porphyrias / Q000188:drug therapy*
D000700:Analgesics; D000777:Anesthetics; D014151:Anti-Anxiety Agents; D000900:Anti-Bacterial Agents; D000893:Anti-Inflammatory Agents; D000927:Anticonvulsants; D000959:Antihypertensive Agents; D000962:Antimalarials; D000697:Central Nervous System Stimulants; D004232:Diuretics; D000431:Ethanol